American College of Rheumatology 2010 recommendations for the prevention and treatment of glucocorticoid‐induced osteoporosis

Saved in:
Bibliographic Details
Published inArthritis care & research (2010) Vol. 62; no. 11; pp. 1515 - 1526
Main Authors Grossman, Jennifer M., Gordon, Rebecca, Ranganath, Veena K., Deal, Chad, Caplan, Liron, Chen, Weiling, Curtis, Jeffrey R., Furst, Daniel E., McMahon, Maureen, Patkar, Nivedita M., Volkmann, Elizabeth, Saag, Kenneth G.
Format Journal Article
LanguageEnglish
Published Hoboken, USA John Wiley & Sons, Inc 01.11.2010
Subjects
Glucocorticoids - adverse effects
Humans
Osteoporosis - chemically induced
Osteoporosis - prevention & control
Osteoporosis - therapy
Practice Guidelines as Topic - standards
Rheumatology - standards
Rheumatology - trends
Societies, Medical - standards
Societies, Medical - trends
Treatment Outcome
United States
United States
Online AccessGet full text

Cover

More Information
Bibliography:Members of the Task Force Panel: Robert Adler, MD (McGuire VA Medical Center, Richmond, VA), Gary Bryant, MD (University of Minnesota, Minneapolis), Cathleen Colon‐Emeric, MD, MHSc (Duke University, Durham, NC), Chad Deal, MD (Cleveland Clinic, Cleveland, OH), Joseph Flood, MD (Musculoskeletal Medical Specialists, Columbus, OH), Theodore Hahn, MD (VA Greater Los Angeles Healthcare System GRECC and University of California, Los Angeles), Amye Leong, MBA (Healthy Motivation, Santa Barbara, CA), Michael Maricic, MD (University of Arizona, Tucson), Anthony Sebba, MD (University of South Florida, Tampa), Stuart Silverman, MD (University of California, Los Angeles).
The American College of Rheumatology is an independent professional, medical, and scientific society which does not guarantee, warrant, or endorse any commercial product or service.
Members of the Expert Advisory Panel: Johannes W. J. Bijlsma, MD (University of Utrecht, Utrecht, The Netherlands), Chad Deal, MD (Cleveland Clinic, Cleveland, OH), Nancy Lane, MD (University of California, Davis), Marc Hochberg, MD, MPH (University of Maryland, Baltimore), Willem Lems, MD (Vrije Universiteit Medical Centre, Amsterdam, The Netherlands), Catherine MacLean, MD, PhD (WellPoint, Inc., Thousand Oaks, CA).
Dr. Deal has received consultant fees, speaking fees, and/or honoraria (more than $10,000 each) from Lilly, Amgen, and Genentech.
Members of the Core Executive Panel: Jennifer M. Grossman, MD, Veena K. Ranganath, MD, Weiling Chen, MA, Daniel E. Furst, MD, Maureen McMahon, MD, MSc, Elizabeth Volkmann, MD, Rebecca Gordon, MD, Kenneth G. Saag, MD, MSc, Jeffrey R. Curtis, MD, MPH, Nivedita M. Patkar, Liron Caplan, MD.
Dr. Curtis has received consultant fees, speaking fees, and/or honoraria (less than $10,000 each) from Eli Lilly and Procter & Gamble, and (more than $10,000 each) from Novartis, Amgen, Roche/Genentech, and Merck.
Dr. Saag has received consultant fees, speaking fees, and/or honoraria (less than $10,000 each) from Merck, Lilly, Novartis, Aventis, Genentech, AstraZeneca, Pfizer, and Horizon.
ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
ObjectType-Review-3
content type line 23
ISSN:2151-464X
2151-4658
2151-4658
DOI:10.1002/acr.20295